Cannabis company Halo Collective Inc. (NEO: HALO) (OTCPK: HCANF) (FSE: A9K0) reported Tuesday its financial results for the second quarter of 2023 revealing revenue of $3.57 million down by 48.1% lower than in the same period of 2022.
Mizuho Securities initiates coverage on Enliven Therapeutics. Expectations high for late 2024 Phase 1 results. Enliven poised to revolutionize CML treatment, addressing current TKI limitations. Mizuho bullish with Buy rating, $34 price target. ELVN's trading value suggests conservative estimation compared to CML market potential.